Fragmentation of Apolipoprotein E4 is Required for Differential Expression of Inflammation and Activation Related Genes in Microglia Cells

Troy T. Rohn, James D. Beck, Stephanie J. Galla, Noail F. Isho, Tanner B Pollock, Tarun Suresh, Arni Kulkarni, Tanya Sanghal, Eric J. HaydenInternational Journal of Neurodegenerative Disorders 2021 · DOI

Abstract

The apolipoprotein E4 (APOE4) allele is the most significant genetic risk factor for late-onset Alzheimer's disease (AD). Emerging evidence suggests that the proteolytic fragmentation of ApoE4, resulting in a toxic gain-of-function, may be a critical molecular driver of AD pathology. Previous research identified a 151 amino-terminal fragment of ApoE4 (nApoE4$_{1-151}$) that localizes to the nuclei of microglia in human AD brains and triggers inflammatory activation in vitro. This study compares the transcriptomic profiles of BV2 microglia cells treated with either full-length ApoE4 (FL-ApoE4) or the nApoE4$_{1-151}$ fragment. Our results demonstrate that while the fragment induces massive up-regulation of over 1,600 genes related to inflammation, the full-length protein remains relatively inert, affecting only 48 genes. These findings suggest that the conversion of microglia to a pro-inflammatory phenotype requires the proteolytic cleavage of FL-ApoE4, highlighting a potential therapeutic target for AD.

Introduction

While the link between APOE4 and Alzheimer’s Disease is well-established, the precise mechanism by which this lipid-transport protein contributes to neurodegeneration remains unclear. The "toxic gain-of-function" hypothesis posits that the primary pathological agent is not the intact protein, but rather specific fragments generated by enzymatic cleavage.

This study addresses whether fragmentation is the necessary "switch" for microglial activation. By comparing the gene expression profiles of microglia exposed to both the full-length protein and its 151 amino-acid amino-terminal fragment, researchers sought to determine if the full-length protein possesses the same inflammatory potential as its truncated counterpart.

Methods

The study utilized BV2 cells, a murine microglial cell line, treated with 25 µg/ml of either human FL-ApoE4 or the nApoE4$_{1-151}$ fragment. The experimental workflow included:

  • Immunocytochemistry: Fluorescent labeling was used to visualize the intracellular localization of the ApoE4 variants.
  • RNA-sequencing (RNA-seq): Global gene activity was captured using an Illumina HiSeq4000 platform.
  • Bioinformatics: Reads were mapped to the mouse reference genome (GRCm39), and differentially expressed genes (DEGs) were identified using DESeq2 (p < 0.05, > 2-fold change).
  • Functional Analysis: The PANTHER classification system was employed for Gene Ontology (GO) analysis to categorize the biological roles of the identified DEGs.

Key Insights and Results

Differential Cellular Localization

A critical finding of this study is the distinct spatial distribution of the two protein forms. The nApoE4$_{1-151}$ fragment exhibits strong nuclear localization, suggesting it may function as a transcription factor or nuclear modulator. In contrast, FL-ApoE4 remains primarily sequestered in the cytoplasm.

Immunocytochemistry showing nuclear localization of the ApoE4 fragment (C) compared to control/FL-ApoE4 (B).

Transcriptomic Impact: Fragment vs. Full-Length

The transcriptomic response to FL-ApoE4 was remarkably minimal compared to the fragment. Only 48 DEGs were identified for FL-ApoE4, whereas previous work showed the fragment altered thousands of genes.

  • Up-regulated Genes: The most significantly increased gene under FL-ApoE4 treatment was Gm33661 (154-fold), a predicted lncRNA. Pcsk5, involved in lipid metabolism, was also significantly up-regulated (22.5-fold).
  • Opposing Inflammatory Profiles: Interestingly, FL-ApoE4 appeared to have a mild anti-inflammatory effect, down-regulating key cytokines such as Il27 (-5.69-fold) and Il23a (-4.00-fold). Conversely, the nApoE4$_{1-151}$ fragment up-regulated these same genes by 183-fold and 14.1-fold, respectively. A strong negative correlation (Pearson’s r = -0.7) was observed between the gene expression changes induced by the two forms.

Discussion and Future Directions

These results support the hypothesis that fragmentation is a literal "toxic gain-of-function." Cleavage does not merely deactivate the protein's lipid-transport role; it transforms it into a potent pro-inflammatory signal that migrates to the nucleus.

While the use of the BV2 mouse cell line is a limitation, the stark contrast in gene expression profiles provides a compelling case for the role of ApoE4 fragments in AD-related neuroinflammation. Future research must identify the specific proteases responsible for this cleavage in the human brain. Therapeutically, these findings suggest that specifically neutralizing the 151 amino-terminal fragment—rather than the full-length protein—may be a more precise and effective strategy for treating Alzheimer's Disease.

Summary updated

Abstract

The apolipoprotein E4 (<i>APOE4</i>) allele represents the single greatest risk factor for late-onset Alzheimer's disease (AD) and accumulating evidence suggests that fragmentation with a toxic-gain of function may be a key molecular step associated with this risk. Recently, we demonstrated strong immunoreactivity of a 151 amino-terminal fragment of apoE4 (E4-fragment) within the nucleus of microglia in the human AD brain. In vitro, this fragment led to toxicity and activation of inflammatory processes in BV2 microglia cells. Additionally, a transcriptome analysis following exogenous treatment of BV2 microglia cells with this E4 fragment led to a > 2-fold up regulation of 1,608 genes, with many genes playing a role in inflammation and microglia activation. To extend these findings, we here report a similar transcriptome analysis in BV2 microglia cells following treatment with full-length ApoE4 (FL-ApoE4). The results indicated that full-length ApoE4 had a very small effect on gene expression compared to the fragment. Only 48 differentially expressed genes (DEGs) were identified (p < 0.05, and greater than 2-fold change). A gene ontology analysis of these DEGs indicated that they are not involved in inflammatory and activation processes, in contrast to the genes up regulated by the E4-fragment. In addition, genes that showed a negative fold-change upon FL-E4 treatment typically showed a strong positive fold-change upon treatment with the fragment (Pearson's r = -0.7). Taken together, these results support the hypothesis that a key step in the conversion of microglia to an activated phenotype is proteolytic cleavage of FL-ApoE4. Therefore, the neutralization of this amino-terminal fragment of ApoE4, specifically, may serve as an important therapeutic strategy in the treatment of AD.
BibTeX
@article{rohn2021fragmentation,
  author = {Troy T. Rohn and James D. Beck and Stephanie J. Galla and Noail F. Isho and Tanner B Pollock and Tarun Suresh and Arni Kulkarni and Tanya Sanghal and Eric J. Hayden},
  title = {{Fragmentation of Apolipoprotein E4 is Required for Differential Expression of Inflammation and Activation Related Genes in Microglia Cells}},
  journal = {International Journal of Neurodegenerative Disorders},
  year = {2021},
  doi = {10.23937/2643-4539/1710020},
}
Figure